Biotech

Oncodesign x TiumBio signed a collaboration agreement | Fibrosis
Biotech
21/10/2021

Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Biotech
Financial
24/06/2021

Oncodesign provides an update on its progress on RIPK2

[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.

Biotech
12/06/2021

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Biotech
01/09/2020

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

Biotech
31/03/2019

Nanocyclix: next generation kinase therapeutics A chemocentric approach for the discovery of selective kinase inhibitors

Nanocyclix: next generation kinase therapeuticsA chemocentric approach for the discovery of selective kinase inhibitors